Long-term oral etoposide in metastatic breast cancer: clinical and pharmacokinetic results.

@article{Calvert1993LongtermOE,
  title={Long-term oral etoposide in metastatic breast cancer: clinical and pharmacokinetic results.},
  author={Alan Hilary Calvert and MichaelJ. Lind and Michael J. Millward and BrianM. J. Cantwell and Lindsey A. Gumbrell and Madeleine Proctor and David Simmons and Fiona M Chapman and A. P. Robinson and Christopher J. Charlton},
  journal={Cancer treatment reviews},
  year={1993},
  volume={19 Suppl C},
  pages={
          27-33
        }
}
To evaluate the activity of long-term, single-agent oral etoposide against advanced breast cancer, this study employed etoposide 50 mg/day and 100 mg/day (given over 14 days) in previously treated and chemotherapy-naive patients with histologically confirmed, recurrent or metastatic breast cancer. Of 38 patients, 24 had had chemotherapy, 34 had prior radiotherapy, and 31 had received hormone therapy. Etoposide courses in both treatment groups were repeated every 4 weeks for at least two courses… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 12 CITATIONS

Similar Papers

Loading similar papers…